Clonidine inhibits anti-non-Gal IgM xenoantibody elicited in multiple pig-to-primate models

John M. Stewart, Alice F Tarantal, Wayne J. Hawthorne, Evelyn J. Salvaris, Philip J. O'Connell, Mark B. Nottle, Anthony J F D'Apice, Peter J. Cowan, Mary Kearns-Jonker

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Survival of vascularized xenografts is dependent on pre-emptive inhibition of the xenoantibody response against galactosyltransferase knockout (GTKO) porcine organs. Our analysis in multiple GTKO pig-to-primate models of xenotransplantation has demonstrated that the anti-non-gal-α-1,3-gal (anti-non-Gal) xenoantibody response displays limited structural diversity. This allowed our group to identify an experimental compound which selectively inhibited induced anti-non-Gal IgM xenoantibodies. However, because this compound had an unknown safety profile, we extended this line of research to include screening small molecules with known safety profiles allowing rapid advancement to large animal models. Methods The NIH clinical collections of small molecules were screened by ELISA for their ability to inhibit xenoantibody binding to GTKO pig endothelial cells. Serum collected from non-immunosuppressed rhesus monkeys at day 14 post-injection with GTKO pig endothelial cells was utilized as a source of elicited xenoantibody for initial screening. Virtual small molecule screening based on xenoantibody structure was used to assess the likelihood that the identified small molecules bound xenoantibody directly. As a proxy for selectivity, ELISAs against tetanus toxoid and the natural antigens laminin, thyroglobulin, and single-stranded DNA (ssDNA) were utilized to assess the ability of the identified reagents to inhibit additional antibody responses. The identified inhibitory small molecules were further tested for their ability to inhibit xenoantibody elicited in multiple settings, including rhesus monkeys pre-treated with an anti-non-Gal selective anti-idiotypic antibody, non-immunosuppressed rhesus monkeys immunized with wild-type fetal pig isletlike cell clusters, and non-immunosuppressed baboons transplanted with GTKO multiple transgenic pig kidneys. Results Four clinically relevant small molecules inhibited anti-non-Gal IgM binding to GTKO pig endothelial cells in vitro. Three of these drugs displayed a limited region of structural similarity suggesting they may inhibit xenoantibody by a similar mechanism. One of these, the anti-hypertensive agent clonidine, displayed only minimal inhibition of antibodies elicited by vaccination against tetanus toxoid or pre-existing natural antibodies against laminin, thyroglobulin, or ssDNA. Furthermore, clonidine inhibited elicited anti-non-Gal IgM from all animals that demonstrated a xenoantibody response in each experimental setting. Conclusions Clinically relevant small molecule drugs with known safety profiles can inhibit xenoantibody elicited against non-Gal antigens in diverse experimental xenotransplantation settings. These molecules are ready to be tested in large animal models. However, it will first be necessary to optimize the timing and dosing required to inhibit xenoantibodies in vivo.

Original languageEnglish (US)
Pages (from-to)413-426
Number of pages14
JournalXenotransplantation
Volume22
Issue number6
DOIs
StatePublished - Nov 1 2015

Fingerprint

Heterophile Antibodies
Clonidine
Primates
Immunoglobulin M
Swine
Galactosyltransferases
Macaca mulatta
Heterologous Transplantation
Tetanus Toxoid
Endothelial Cells
Thyroglobulin
Single-Stranded DNA
Laminin
Safety
Animal Models
Enzyme-Linked Immunosorbent Assay
Antigens
Antibodies
Papio
Proxy

Keywords

  • baboon
  • clonidine
  • endothelial cell
  • islet
  • kidney
  • pig
  • rhesus monkey
  • small molecule
  • xenotransplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Stewart, J. M., Tarantal, A. F., Hawthorne, W. J., Salvaris, E. J., O'Connell, P. J., Nottle, M. B., ... Kearns-Jonker, M. (2015). Clonidine inhibits anti-non-Gal IgM xenoantibody elicited in multiple pig-to-primate models. Xenotransplantation, 22(6), 413-426. https://doi.org/10.1111/xen.12199

Clonidine inhibits anti-non-Gal IgM xenoantibody elicited in multiple pig-to-primate models. / Stewart, John M.; Tarantal, Alice F; Hawthorne, Wayne J.; Salvaris, Evelyn J.; O'Connell, Philip J.; Nottle, Mark B.; D'Apice, Anthony J F; Cowan, Peter J.; Kearns-Jonker, Mary.

In: Xenotransplantation, Vol. 22, No. 6, 01.11.2015, p. 413-426.

Research output: Contribution to journalArticle

Stewart, JM, Tarantal, AF, Hawthorne, WJ, Salvaris, EJ, O'Connell, PJ, Nottle, MB, D'Apice, AJF, Cowan, PJ & Kearns-Jonker, M 2015, 'Clonidine inhibits anti-non-Gal IgM xenoantibody elicited in multiple pig-to-primate models', Xenotransplantation, vol. 22, no. 6, pp. 413-426. https://doi.org/10.1111/xen.12199
Stewart, John M. ; Tarantal, Alice F ; Hawthorne, Wayne J. ; Salvaris, Evelyn J. ; O'Connell, Philip J. ; Nottle, Mark B. ; D'Apice, Anthony J F ; Cowan, Peter J. ; Kearns-Jonker, Mary. / Clonidine inhibits anti-non-Gal IgM xenoantibody elicited in multiple pig-to-primate models. In: Xenotransplantation. 2015 ; Vol. 22, No. 6. pp. 413-426.
@article{af5ff95312d44e29ba0d9bedba1b32bf,
title = "Clonidine inhibits anti-non-Gal IgM xenoantibody elicited in multiple pig-to-primate models",
abstract = "Background Survival of vascularized xenografts is dependent on pre-emptive inhibition of the xenoantibody response against galactosyltransferase knockout (GTKO) porcine organs. Our analysis in multiple GTKO pig-to-primate models of xenotransplantation has demonstrated that the anti-non-gal-α-1,3-gal (anti-non-Gal) xenoantibody response displays limited structural diversity. This allowed our group to identify an experimental compound which selectively inhibited induced anti-non-Gal IgM xenoantibodies. However, because this compound had an unknown safety profile, we extended this line of research to include screening small molecules with known safety profiles allowing rapid advancement to large animal models. Methods The NIH clinical collections of small molecules were screened by ELISA for their ability to inhibit xenoantibody binding to GTKO pig endothelial cells. Serum collected from non-immunosuppressed rhesus monkeys at day 14 post-injection with GTKO pig endothelial cells was utilized as a source of elicited xenoantibody for initial screening. Virtual small molecule screening based on xenoantibody structure was used to assess the likelihood that the identified small molecules bound xenoantibody directly. As a proxy for selectivity, ELISAs against tetanus toxoid and the natural antigens laminin, thyroglobulin, and single-stranded DNA (ssDNA) were utilized to assess the ability of the identified reagents to inhibit additional antibody responses. The identified inhibitory small molecules were further tested for their ability to inhibit xenoantibody elicited in multiple settings, including rhesus monkeys pre-treated with an anti-non-Gal selective anti-idiotypic antibody, non-immunosuppressed rhesus monkeys immunized with wild-type fetal pig isletlike cell clusters, and non-immunosuppressed baboons transplanted with GTKO multiple transgenic pig kidneys. Results Four clinically relevant small molecules inhibited anti-non-Gal IgM binding to GTKO pig endothelial cells in vitro. Three of these drugs displayed a limited region of structural similarity suggesting they may inhibit xenoantibody by a similar mechanism. One of these, the anti-hypertensive agent clonidine, displayed only minimal inhibition of antibodies elicited by vaccination against tetanus toxoid or pre-existing natural antibodies against laminin, thyroglobulin, or ssDNA. Furthermore, clonidine inhibited elicited anti-non-Gal IgM from all animals that demonstrated a xenoantibody response in each experimental setting. Conclusions Clinically relevant small molecule drugs with known safety profiles can inhibit xenoantibody elicited against non-Gal antigens in diverse experimental xenotransplantation settings. These molecules are ready to be tested in large animal models. However, it will first be necessary to optimize the timing and dosing required to inhibit xenoantibodies in vivo.",
keywords = "baboon, clonidine, endothelial cell, islet, kidney, pig, rhesus monkey, small molecule, xenotransplantation",
author = "Stewart, {John M.} and Tarantal, {Alice F} and Hawthorne, {Wayne J.} and Salvaris, {Evelyn J.} and O'Connell, {Philip J.} and Nottle, {Mark B.} and D'Apice, {Anthony J F} and Cowan, {Peter J.} and Mary Kearns-Jonker",
year = "2015",
month = "11",
day = "1",
doi = "10.1111/xen.12199",
language = "English (US)",
volume = "22",
pages = "413--426",
journal = "Xenotransplantation",
issn = "0908-665X",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Clonidine inhibits anti-non-Gal IgM xenoantibody elicited in multiple pig-to-primate models

AU - Stewart, John M.

AU - Tarantal, Alice F

AU - Hawthorne, Wayne J.

AU - Salvaris, Evelyn J.

AU - O'Connell, Philip J.

AU - Nottle, Mark B.

AU - D'Apice, Anthony J F

AU - Cowan, Peter J.

AU - Kearns-Jonker, Mary

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Background Survival of vascularized xenografts is dependent on pre-emptive inhibition of the xenoantibody response against galactosyltransferase knockout (GTKO) porcine organs. Our analysis in multiple GTKO pig-to-primate models of xenotransplantation has demonstrated that the anti-non-gal-α-1,3-gal (anti-non-Gal) xenoantibody response displays limited structural diversity. This allowed our group to identify an experimental compound which selectively inhibited induced anti-non-Gal IgM xenoantibodies. However, because this compound had an unknown safety profile, we extended this line of research to include screening small molecules with known safety profiles allowing rapid advancement to large animal models. Methods The NIH clinical collections of small molecules were screened by ELISA for their ability to inhibit xenoantibody binding to GTKO pig endothelial cells. Serum collected from non-immunosuppressed rhesus monkeys at day 14 post-injection with GTKO pig endothelial cells was utilized as a source of elicited xenoantibody for initial screening. Virtual small molecule screening based on xenoantibody structure was used to assess the likelihood that the identified small molecules bound xenoantibody directly. As a proxy for selectivity, ELISAs against tetanus toxoid and the natural antigens laminin, thyroglobulin, and single-stranded DNA (ssDNA) were utilized to assess the ability of the identified reagents to inhibit additional antibody responses. The identified inhibitory small molecules were further tested for their ability to inhibit xenoantibody elicited in multiple settings, including rhesus monkeys pre-treated with an anti-non-Gal selective anti-idiotypic antibody, non-immunosuppressed rhesus monkeys immunized with wild-type fetal pig isletlike cell clusters, and non-immunosuppressed baboons transplanted with GTKO multiple transgenic pig kidneys. Results Four clinically relevant small molecules inhibited anti-non-Gal IgM binding to GTKO pig endothelial cells in vitro. Three of these drugs displayed a limited region of structural similarity suggesting they may inhibit xenoantibody by a similar mechanism. One of these, the anti-hypertensive agent clonidine, displayed only minimal inhibition of antibodies elicited by vaccination against tetanus toxoid or pre-existing natural antibodies against laminin, thyroglobulin, or ssDNA. Furthermore, clonidine inhibited elicited anti-non-Gal IgM from all animals that demonstrated a xenoantibody response in each experimental setting. Conclusions Clinically relevant small molecule drugs with known safety profiles can inhibit xenoantibody elicited against non-Gal antigens in diverse experimental xenotransplantation settings. These molecules are ready to be tested in large animal models. However, it will first be necessary to optimize the timing and dosing required to inhibit xenoantibodies in vivo.

AB - Background Survival of vascularized xenografts is dependent on pre-emptive inhibition of the xenoantibody response against galactosyltransferase knockout (GTKO) porcine organs. Our analysis in multiple GTKO pig-to-primate models of xenotransplantation has demonstrated that the anti-non-gal-α-1,3-gal (anti-non-Gal) xenoantibody response displays limited structural diversity. This allowed our group to identify an experimental compound which selectively inhibited induced anti-non-Gal IgM xenoantibodies. However, because this compound had an unknown safety profile, we extended this line of research to include screening small molecules with known safety profiles allowing rapid advancement to large animal models. Methods The NIH clinical collections of small molecules were screened by ELISA for their ability to inhibit xenoantibody binding to GTKO pig endothelial cells. Serum collected from non-immunosuppressed rhesus monkeys at day 14 post-injection with GTKO pig endothelial cells was utilized as a source of elicited xenoantibody for initial screening. Virtual small molecule screening based on xenoantibody structure was used to assess the likelihood that the identified small molecules bound xenoantibody directly. As a proxy for selectivity, ELISAs against tetanus toxoid and the natural antigens laminin, thyroglobulin, and single-stranded DNA (ssDNA) were utilized to assess the ability of the identified reagents to inhibit additional antibody responses. The identified inhibitory small molecules were further tested for their ability to inhibit xenoantibody elicited in multiple settings, including rhesus monkeys pre-treated with an anti-non-Gal selective anti-idiotypic antibody, non-immunosuppressed rhesus monkeys immunized with wild-type fetal pig isletlike cell clusters, and non-immunosuppressed baboons transplanted with GTKO multiple transgenic pig kidneys. Results Four clinically relevant small molecules inhibited anti-non-Gal IgM binding to GTKO pig endothelial cells in vitro. Three of these drugs displayed a limited region of structural similarity suggesting they may inhibit xenoantibody by a similar mechanism. One of these, the anti-hypertensive agent clonidine, displayed only minimal inhibition of antibodies elicited by vaccination against tetanus toxoid or pre-existing natural antibodies against laminin, thyroglobulin, or ssDNA. Furthermore, clonidine inhibited elicited anti-non-Gal IgM from all animals that demonstrated a xenoantibody response in each experimental setting. Conclusions Clinically relevant small molecule drugs with known safety profiles can inhibit xenoantibody elicited against non-Gal antigens in diverse experimental xenotransplantation settings. These molecules are ready to be tested in large animal models. However, it will first be necessary to optimize the timing and dosing required to inhibit xenoantibodies in vivo.

KW - baboon

KW - clonidine

KW - endothelial cell

KW - islet

KW - kidney

KW - pig

KW - rhesus monkey

KW - small molecule

KW - xenotransplantation

UR - http://www.scopus.com/inward/record.url?scp=84950290777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950290777&partnerID=8YFLogxK

U2 - 10.1111/xen.12199

DO - 10.1111/xen.12199

M3 - Article

VL - 22

SP - 413

EP - 426

JO - Xenotransplantation

JF - Xenotransplantation

SN - 0908-665X

IS - 6

ER -